✦ LIBER ✦

The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro

✍ Scribed by George W. Cole Jr; Annette M. Alleva; Rishindra M. Reddy; Justin B. Maxhimer; JingTong Zuo; David S. Schrump; Dao M. Nguyen

Book ID: 113759952
Publisher: CTSNet
Year: 2005
Tongue: English
Weight: 564 KB
Volume: 129
Category: Article
ISSN: 1097-685X
DOI: 10.1016/j.jtcvs.2004.10.040

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A potent protein-tyrosine kinase inhibit

A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo

✍ Nicholas B. Lydon; Helmut Mett; Marcel Mueller; Michael Becker; Robert M. Cozens 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 243 KB 👁 2 views

Antitumor activity of the selective epid

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo

✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell

Effects of combined valproic acid and th

Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro

✍ Eva Juengel; Johanna Engler; Ausra Mickuckyte; Jon Jones; Lukasz Hudak; Dietger 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 509 KB

The DNA-binding epidermal growth factor-

The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-β tumor-suppressor gene in breast cancer cells

✍ Thomas W. Grunt; Katharina Tomek; Renate Wagner; Klaudia Puckmair; Christoph C. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB

A potent protein-tyrosine kinase inhibit

A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo. Int. J. Cancer,76, 154–163 (1998)

✍ N. Lydon; H. Mett; M. Mueller; M. Becker; R.M. Cozens; D. Daniels; P. Traxler; E 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 8 KB 👁 2 views

Additive antitumor effects of the epider

Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro

✍ Claudio Festuccia; Giovanni Luca Gravina; Adriano Angelucci; Danilo Millimaggi; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 618 KB

## Abstract Progression from an androgen‐dependent to an androgen‐independent state often occurs in patients with prostate cancer (PCa) who undergo hormonal therapy. We have investigated whether inhibition of the epidermal growth factor receptor (EGFR) signaling pathway affects the antitumor effect